Adherence in patients transferred from immediate release metformin to a sustained release formulation: A population-based study

Diabetes, Obesity and Metabolism

Volumn 11, Issue 4, 2009, Pages 338-342

  Donnelly, L A ^a   Morris, A D ^a   Pearson, Ewan R ^a,b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adherence; Glucophage SR; Metformin; Metformin XL

Indexed keywords

GLUCOPHAGE SR; HEMOGLOBIN A1C; METFORMIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT COMPLIANCE; POPULATION RESEARCH; SUSTAINED RELEASE FORMULATION; AGED; BLOOD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; MEDICAL RECORD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM;

AGED; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAL RECORD LINKAGE; METFORMIN; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SCOTLAND;

EID: 61549086881     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00973.x     Document Type: Article

References (16)

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 12; 352: 854-865.
2. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
3. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-497.
4. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: A retrospective cohort study. Diabet Med 2002; 19: 279-284.
5. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005; 44: 721-729.
6. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther 2003; 25: 515-529.
7. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: Results of a retrospective cohort study. Curr Med Res Opin 2004; 20: 565-572.
8. Type 2 diabetes: Full guideline. Royal College of Physicians 2008.
9. Morris A, Boyle D, MacAlpine R, et al. The diabetes audit and research in Tayside Scotland (DARTS) study: Electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 1997; 315: 524-528.
10. Evans J, McDevitt D, MacDonald T. The Tayside Medicines Monitoring Unit (MEMO): A record-linkage system for pharmacovigilance. Pharm Med 1995; 9: 177-184.
11. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 2003; London: BMJ Books.
12. Donnan P, MacDonald T, Morris A. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: A retrospective cohort study. Diabet Med 2002; 19: 279-284.
13. Pearson E, Donnelly L, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes 2007; 56: 2178-2182.
14. Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005; 7: 722-728.
15. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: Results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 2005; 7: 28-39.
16. Gao H, Xiao W, Wang C, et al. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: A multicentre study. Int J Clin Pract 2008; 62: 695-700.